A double mutation of MBP83-99 peptide induces IL-4 responses and antagonizes IFN-γ responses

Journal of Neuroimmunology

Volumn 200, Issue 1-2, 2008, Pages 77-89

  Katsara, Maria ^a,b   Yuriev, Elizabeth ^c   Ramsland, Paul A ^a   Deraos, George ^b   Tselios, Theodore ^b   Matsoukas, John ^b   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF PATRAS   (Greece)

^c MONASH UNIVERSITY   (Australia)

Author keywords

I As; MBP; Modeling; MS; Mutation; Vaccine

Indexed keywords

ALANINE; AMINO ACID; ARGININE; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 4; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[83-99]; PHENYLALANINE; T LYMPHOCYTE RECEPTOR; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE RELEASE; IMMUNE RESPONSE; INTERFERON PRODUCTION; MOLECULAR MODEL; MULTIPLE SCLEROSIS; MUTATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SWISS JAMES LAMBERT MOUSE; T LYMPHOCYTE;

ANIMALS; CELL COUNT; CELL PROLIFERATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MODELS, MOLECULAR; MUTATION; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TIME FACTORS;

EID: 47549085907     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.06.013     Document Type: Article

References (44)

1. Barlos K., and Gatos D. 9-Fluorenylmethyloxycarbonyl/ tbutyl-based convergent protein synthesis. Biopolymers 51 (1999) 266-278
2. Barlos K., Gatos D., and Koutsogianni S. Fmoc/Trt-amino acids: comparison to Fmoc/tBu-amino acids in peptide synthesis. J. Pept. Res. 51 (1998) 194-200
3. Begolka W.S., and Miller S.D. Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental autoimmune encephalomyelitis. Res. Immunol. 149 (1998) 771-781 discussion 843-4, 855-60
4. Bhardwaj V., Kumar V., Grewal I.S., Dao T., Lehmann P.V., Geysen H.M., and Sercarz E.E. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their F1S. J. Immunol. 152 (1994) 3711-3719
5. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., and Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 (2000) 1167-1175
6. Crowe P.D., Qin Y., Conlon P.J., and Antel J.P. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 48 (2000) 758-765
7. de Haan E.C., Moret E.E., Wagenaar-Hilbers J.P., Liskamp R.M., and Wauben M.H. Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy. Mol. Immunol. 42 (2005) 365-373
8. Franco A., Southwood S., Arrhenius T., Kuchroo V.K., Grey H.M., Sette A., and Ishioka G.Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 24 (1994) 940-946
9. Gaertner S., de Graaf K.L., Greve B., and Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63 (2004) 2381-2383
10. Gauthier L., Smith K.J., Pyrdol J., Kalandadze A., Strominger J.L., Wiley D.C., and Wucherpfennig K.W. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 11828-11833
11. Greer J.M., Sobel R.A., Sette A., Southwood S., Lees M.B., and Kuchroo V.K. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J. Immunol. 156 (1996) 371-379
12. Hafler D.A., and Weiner H.L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144 (1995) 75-107
13. He X.L., Radu C., Sidney J., Sette A., Ward E.S., and Garcia K.C. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au. Immunity 17 (2002) 83-94
14. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 291-301
15. Imitola J., Chitnis T., and Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 106 (2005) 163-177
16. Kalbus M., Fleckenstein B.T., Offenhausser M., Bluggel M., Melms A., Meyer H.E., Rammensee H.G., Martin R., Jung G., and Sommer N. Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s). Eur. J. Immunol. 31 (2001) 551-562
17. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., and Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS Study Group. Nat. Med. 6 (2000) 1176-1182
18. Karin N., Mitchell D.J., Brocke S., Ling N., and Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180 (1994) 2227-2237
19. 83-99 peptides diverts immune responses from Th1 to Th2. Molecular Immunology 45 (2008) 3661-3670
20. 83-99 modulate immune responses in SJL/J mice. J. of Med. Chem. 51 (2008) 3971-3978
21. Kim H.J., Antel J.P., Duquette P., Alleva D.G., Conlon P.J., and Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin. Immunol. 104 (2002) 105-114
22. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007) 774-797
23. Kuchroo V.K., Sobel R.A., Laning J.C., Martin C.A., Greenfield E., Dorf M.E., and Lees M.B. Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein. Fine specificity and T cell receptor V beta usage. J. Immunol. 148 (1992) 3776-3782
24. Kuchroo V.K., Greer J.M., Kaul D., Ishioka G., Franco A., Sette A., Sobel R.A., and Lees M.B. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153 (1994) 3326-3336
25. Li Y., Huang Y., Lue J., Quandt J.A., Martin R., and Mariuzza R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 24 (2005) 2968-2979
26. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E.O., McFarlin D.E., and McFarland H.F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145 (1990) 540-548
27. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10 (1992) 153-187
28. Matsoukas J., Apostolopoulos V., Kalbacher H., Papini A.M., Tselios T., Chatzantoni K., Biagioli T., Lolli F., Deraos S., Papathanassopoulos P., Troganis A., Mantzourani E., Mavromoustakos T., and Mouzaki A. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem. 48 (2005) 1470-1480
29. Noseworthy J.H., Gold R., and Hartung H.P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr. Opin. Neurol. 12 (1999) 279-293
30. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., and Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
31. Pette M., Fujita K., Wilkinson D., Altmann D.M., Trowsdale J., Giegerich G., Hinkkanen A., Epplen J.T., Kappos L., and Wekerle H. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7968-7972
32. Reizis B., Eisenstein M., Mor F., and Cohen I.R. The peptide-binding strategy of the MHC class II I-A molecules. Immunol. Today 19 (1998) 212-216
33. Rudensky A., Preston-Hurlburt P., al-Ramadi B.K., Rothbard J., and Janeway Jr. C.A. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 359 (1992) 429-431
34. Smilek D.E., Wraith D.C., Hodgkinson S., Dwivedy S., Steinman L., and McDevitt H.O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9633-9637
35. Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., and Wucherpfennig K.W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188 (1998) 1511-1520
36. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.A., and Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79 (1997) 54-61
37. Tselios T., Probert L., Daliani I., Matsoukas E., Troganis A., Gerothanassis I.P., Mavromoustakos T., Moore G.J., and Matsoukas J.M. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem. 42 (1999) 1170-1177
38. Tselios T., Daliani I., Probert L., Deraos S., Matsoukas E., Roy S., Pires J., Moore G., and Matsoukas J. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. Bioorg. Med. Chem. 8 (2000) 1903-1909
39. Wall M., Southwood S., Sidney J., Oseroff C., del Guericio M.F., Lamont A.G., Colon S.M., Arrhenius T., Gaeta F.C., and Sette A. High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int. Immunol. 4 (1992) 773-777
40. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8 (1995) 127-134
41. Williams K.A., and Deber C.M. The structure and function of central nervous system myelin. Crit. Rev. Clin. Lab. Sci. 30 (1993) 29-64
42. Wucherpfennig K.W., Sette A., Southwood S., Oseroff C., Matsui M., Strominger J.L., and Hafler D.A. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179 (1994) 279-290
43. Wucherpfennig K.W., Zhang J., Witek C., Matsui M., Modabber Y., Ota K., and Hafler D.A. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J. Immunol. 152 (1994) 5581-5592
44. Wucherpfennig K.W., Hafler D.A., and Strominger J.L. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8896-8900